Content uploaded by Raphael Mechoulam
Author content
All content in this area was uploaded by Raphael Mechoulam on Jul 15, 2014
Content may be subject to copyright.
A preview of the PDF is not available
Antipsychotic effect of cannabidiol [3]
... THC may enhance cognitive function by triggering the body's natural defense mechanism, shielding the brain from additional harm. On the other hand, CBD is generally well tolerated in humans up to a daily dose of 1,300 mg [65]. According to the World Health Organization (WHO) review data, there is no evidence of health-related problems associated with the recreational use of pure CBD [66] . ...
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
Certain genetic factors, like variations in the COMT and AKT1 genes, may increase an individual’s vulnerability to cannabis-induced psychosis. Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
A small percentage of users may develop schizophrenia or bipolar disorder, while many experience transient psychotic symptoms, such as paranoia and hallucinations. Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
The increasing use of high-THC cannabis, especially among young people, has raised public health concerns about long-term mental health impacts. Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
Identifying vulnerable individuals (e.g., those with family history or schizotypal traits) can help implement early prevention and treatment strategies to mitigate the effects of cannabis on mental health. Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
Not everyone who uses cannabis develops mental health problems. Some may only experience short-term effects like anxiety or paranoia, while others may develop long-term disorders. Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
The endocannabinoid system, involved in regulating mood, cognition, and perception, interacts with other neurotransmitters like dopamine, GABA, and glutamate—systems that play a role in psychotic illnesses like schizophrenia. Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
... Anandamide, a derivative of arachidonic acid, was named after the Sanskrit word for "bliss." Three years later, Mechoulam and colleagues identified a second endocannabinoid neurotransmitter, 2-arachidonylglycerol (2-AG) [Mechoulam et al., 1995]. THC, acting as a partial agonist, has similar binding affinity for CB1R as anandamide, but lower efficacy, particularly at CB2Rs [Pertwee, 2008]. ...
Over the past 15 years, street cannabis strains with higher THC content have become more common, especially variants like “skunk” or “sinsemilla.” Cannabis is a complex plant containing over 400 chemical compounds, including key cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which exert opposing effects. The identification of these compounds has led to the exploration of the endocannabinoid system, a crucial neurotransmitter system widespread in the brain and body, responsible for various significant physiological functions. Recently, there has been a global increase in cannabis potency, raising health concerns. Epidemiological studies indicate a link between dose-dependent cannabis use and an elevated risk of persistent psychotic disorders. However, not all users experience adverse effects equally. The factors that contribute to individual susceptibility remain unclear, although emerging research suggests that genetics and personality traits may play a role. This article first examines the biochemical basis of cannabis and its two primary compounds, followed by a review of the factors that may explain the variability in individual responses to cannabis.
ResearchGate has not been able to resolve any references for this publication.